BMY logo

Bristol-Myers Squibb Company

BMY
Healthcare|Drug Manufacturers - General|US
$62.14
-0.99 (-1.57%)
DCF Value
$239.82
Graham Number
$34.15
Cash / Share
$6.16

Clinical Trials (104)

TrialConditionsPhaseStatusEnrollmentDesignDrug
NCT07681076
Study to Assess Safety and Tolerability of KarXT With Administration of Antiemetics in Healthy Volunteers
Healthy Volunteers
P4
Recruiting180RCT, Open-labelKarXT, Trimethobenzamide, Ondansetron, Meclizine
NCT06126224
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)
Psychosis Associated With Alzheimer's Disease
P3
Recruiting500RCT, Double-blindKarXT, Placebo
NCT05511363
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)
Psychosis Associated With Alzheimer's Disease
P3
Recruiting410RCT, Double-blindKarXT, Placebo
NCT07424404
A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and Adolescents
Schizophrenia, Autism-Related Irritability
P3
Recruiting400Open-labelKarXT, KarX-EC
NCT05980949
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
Psychosis Associated With Alzheimer's Disease
P3
Recruiting1,000Open-labelKarXT
NCT06585787
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
Alzheimer Disease
P3
Recruiting406RCT, Double-blindKarXT, Placebo
NCT07686263
Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia
Schizophrenia
P3
Recruiting472RCT, Double-blindXanomeline/Trospium Chloride, Placebo
NCT06615479
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Relapsed or Refractory Multiple Myeloma (RRMM)
P3
Recruiting440RCT, Open-labelBMS-986393, Cyclophosphamide, Fludarabine, Daratumumab, Pomalidomide, Dexamethasone, Carfilzomib
NCT05702034
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE
Ischemic Stroke; Ischemic Attack, Transient
P3
Active12,523RCT, Double-blindMilvexian, Placebo
NCT07015242
A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
Lymphoma
P2
Recruiting65Open-labelRituximab, Methotrexate, Procarbazine, Temozolomide, Liso-cel, Fludarabine, Cyclophosphamide, Calcium folinate
NCT06297226
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Multiple Myeloma
P2
Recruiting230Open-labelArlocabtagene Autoleucel
NCT03527108
Nivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLC
Non Small Cell Lung Cancer
P2
Active36Open-labelNivolumab, Ramucirumab
NCT02693535
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Lymphoma, Non-Hodgkin, Multiple Myeloma
P2
Recruiting4,200Open-labelSunitinib (CLOSED TO ENROLLMENT), Trastuzumab and Pertuzumab (CLOSED TO ENROLLMENT), Vemurafenib and Cobimetinib (CLOSED TO ENROLLMENT), Olaparib (CLOSED TO ENROLLMENT), Nivolumab and Ipilimumab (CLOSED TO ENROLLMENT), Abemaciclib (CLOSED TO ENROLLMENT), Talazoparib (CLOSED TO ENROLLMENT), Atezolizumab and Talazoparib (CLOSED TO ENROLLMENT), Tucatinib plus Trastuzumab Subcutaneous (SC) (CLOSED TO ENROLLMENT), Futibatinib, Dabrafenib plus Trametinib, Fam-Trastuzumab Deruxtecan-Nxki (TDxD)
NCT02925234
The Drug Rediscovery Protocol (DRUP Trial)
Cancer, Tumors
P2
Recruiting1,550Open-labelPanitumumab, Olaparib, Dabrafenib, Nilotinib, Trametinib, Erlotinib, Trastuzumab and Pertuzumab (combination treatment), Vemurafenib and Cobimetinib (combination treatment), Vismodegib, Regorafenib, Nivolumab, Afatinib, Dabrafenib and trametinib, Ribociclib, Lenvatinib, Pembrolizumab, Durvalumab, Rucaparib, Axitinib, Palbociclib, Crizotinib, Sunitinib, Cabozantinib, Abemaciclib, Alectinib, Atezolizumab and Bevacizumab, Ipilimumab and nivolumab, Entrectinib, Talazoparib, Dacomitinib, Lorlatinib, Erdafitinib, Alpelisib, Niraparib, Pemigatinib, Selpercatinib, Tepotinib
NCT07015983
A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)
Lupus Erythematosus, Systemic, Lupus Nephritis
P2
Active89Open-labelCC-97540, Fludarabine, Cyclophosphamide
NCT06121843
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
Multiple Myeloma
P1
Recruiting187Open-labelBMS-986393, Alnuctamab, Mezigdomide, Iberdomide, Elranatamab, Dexamethasone
NCT07204418
A Study to Evaluate the Effects of CYP2D6 Phenotypes on the Pharmacokinetics of Xanomeline Following KarXT Administration in Healthy Adult Participants
Healthy Volunteers
P1
Recruiting56Open-labelXanomeline/ Trospium Chloride
NCT02498912
Cyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engineered to Secrete IL-12 and to Target the MUC16ecto Antigen in Patients With Recurrent MUC16ecto+ Solid Tumors
Solid Tumors
P1
Active18Open-labelCyclophosphamide, Fludarabine
NCT07115745
A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases
Refractory Autoimmune Diseases
P1
Recruiting125Open-labelFludarabine, Cyclophosphamide, Tocilizumab
NCT06153251
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
Relapsed and/or Refractory Multiple Myeloma
P1
Recruiting187Open-labelBMS-986453, Fludarabine, Cyclophosphamide
NCT06220201
A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)
Multiple Sclerosis, Myasthenia Gravis
P1
Active120Open-labelCC-97540, Fludarabine, Cyclophosphamide
NCT03085173
A Trial of "Armored" CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies
Chronic Lymphocytic Leukemia (CLL), Relapsed
P1
Active39Open-labelEGFRt/19-28z/4-1BBL CAR T cells
NCT05869955
A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)
Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathy
P1
Active270Open-labelCC-97540, Fludarabine, Cyclophosphamide, Tocilizumab
NCT06788652
A Study of Patients With Relapsed/Refractory Mantle Cell Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting
Mantle Cell Lymphoma (MCL)
Recruiting300—Lisocabtagene maraleucel
NCT06788639
A Study of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting
Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
Recruiting300—Lisocabtagene maraleucel
NCT06794268
A Study to Patients With Relapsed/Refractory Follicular Lymphoma Treated With Liso-cel (Lisocabtagene Maraleucel) in the Post Marketing Setting
Follicular Lymphoma
Recruiting300—Lisocabtagene maraleucel
NCT00404989
Antiretroviral Pregnancy Registry (APR): Multi-sponsor Registry to Detect Any Major Teratogenic Effect Involving Any of the Registry Drugs When Administered to Pregnant People.
HIV Infections, Hepatitis B
Recruiting24,258——
NCT00505245
New Assessment System in Measuring Symptom Distress in Cancer Patients
Caregiver, Health Care Provider
Recruiting6,500——
NCT05918666
National Register of Actionable Mutations
Solid Tumours in Advanced Stages
Active2,098——
NCT01848028
PsoBest - The German Psoriasis Registry
Psoriasis, Psoriatic-arthritis
Recruiting3,500——
NCT02622581
Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma Patients
Metastatic Non-small Cell Lung Cancer (NSCLC), Non-small Cell Lung Cancer Metastatic
Recruiting14,500——
NCT05080218
COVID-19 VaccinE Response in Rheumatology Patients
Rheumatoid Arthritis, Psoriatic Arthritis
P4
Completed841RCT, Open-labelUpadacitinib, Abatacept, Secukinumab, Tofacitinib, TNF Inhibitor, Canakinumab Injection, Baricitinib, Ixekizumab
NCT00977938
The Dual Antiplatelet Therapy Study (DAPT Study)
Coronary Artery Disease
P4
Completed25,682RCT, Double-blindPlacebo & Aspirin, Clopidogrel & Aspirin, Prasugrel & Aspirin
NCT00169819
EArly Discharge After Transradial Stenting of CoronarY Arteries: The EASY Study
Coronary Artery Disease, Ischemia
P4
Completed1,000RCT, Open-labelAbciximab
NCT01524705
FLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR)
Type 2 Diabetes
P4
Completed102RCT, Double-blindInsulin Glargine, Metformin, Prandial insulin, Exenatide
NCT01106534
XIENCE V® USA Dual Antiplatelet Therapy (DAPT) Cohort
Chronic Total Occlusion of Coronary Artery, Vascular Disease
P4
Completed870RCT, Double-blindplacebo + aspirin, clopidogrel + aspirin OR prasugrel + aspirin
NCT07257120
KarXT Concentrations in the Breast Milk and Plasma of Lactating Females
Healthy Volunteers
P4
Completed10Open-labelXanomeline/trospium chloride
NCT00816959
Study Evaluating the Effect of R-mabHDI in Lymphocytic Predominant Hodgkin's Lymphoma
Hodgkin's Lymphoma
P3
Unknown1,200RCT, Open-labelR-mabHDI and ABVD, ABVD
NCT04820309
An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-5)
Schizophrenia
P3
Completed566Open-labelXanomeline and Trospium Chloride Capsules
NCT07335562
A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis
Systemic Sclerosis
P3
Not Yet Recruiting92RCT, Open-labelBMS-986353, Fludarabine, Cyclophosphamide, Tocilizumab, Rituximab, Nintedanib
NCT04738123
A Study to Assess Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adult Patients With Schizophrenia (EMERGENT-3)
Schizophrenia, Schizophrenia; Psychosis
P3
Completed256RCT, Double-blindXanomeline and Trospium Chloride Capsules, Placebo
NCT05919823
A Study to Assess the Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Chinese Adult Subjects With DSM-5 Schizophrenia
Schizophrenia
P3
Completed202RCT, Double-blindXanomeline and Trospium Chloride Capsules, Placebo
NCT05643170
An Open-label Study to Assess the Long-term Safety, Tolerability, Effectiveness, and Durability of Effect of KarXT in Patients With DSM-5 Diagnosis of Schizophrenia
Schizophrenia
P3
Terminated4Open-labelXanomeline and Trospium Chloride Capsules
NCT00077233
FOLFIRI or FOLFOX With or Without Cetuximab in Patients With Metastatic Adenocarcinoma of the Colon or Rectum
Colorectal Cancer
P3
Terminated238RCT, Open-labelcetuximab, 5-FU, irinotecan, leucovorin, oxaliplatin
NCT06205290
A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies
Leukemia, Lymphocytic, Chronic, B-Cell
P3
Withdrawn—RCT, Open-labelLiso-cel, Idelalisib, Rituximab, Bendamustine, Fludarabine, Cyclophosphamide
NCT00063141
Study of Irinotecan and Cetuximab Versus Irinotecan as Second-Line Treatment in Patients With Metastatic, EGFR-Positive Colorectal Cancer
Colorectal Cancer
P3
Completed1,302RCT, Open-labelcetuximab, Irinotecan, Irinotecan
NCT04659174
An Extension Study to Assess Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-4)
Schizophrenia
P3
Completed152Open-labelXanomeline and Trospium Chloride Capsules
NCT05145413
A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia
Schizophrenia
P3
Completed396RCT, Double-blindXanomeline and Trospium Chloride Capsules, Placebo
NCT05304767
An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia
Schizophrenia
P3
Completed290Open-labelXanomeline and Trospium Chloride Capsules
NCT04518410
ACTIV-2: A Study for Outpatients With COVID-19
Coronavirus, Covid19
P2P3
Completed4,044RCT, Double-blindbamlanivimab 7000mg, BRII-196+BRII-198, AZD7442 (IV), AZD7442 (IM), SNG001, Camostat, BMS-986414 + BMS-986413, SAB-185 (3,840 Units/kg), SAB-185 (10,240 Units/kg), CASIRIVIMAB + IMDEVIMAB, Placebo for Bamlanivimab 7000mg, Placebo for Bamlanivimab 700mg, Placebo for BRII-196+BRII-198, Placebo for SNG001, Placebo for Camostat, Placebo for SAB-185 (low dose), Placebo for BMS-986414 + BMS-986413, Placebo for AZD7442 (IV), Placebo for AZD7442 (IM), Placebo for SAB-185 (high dose), bamlanivimab 700mg
NCT06572449
Study to Assess Safety and Effectiveness of Slowly Increasing Dose and Food Effect of KarXT in Participants With Schizophrenia
Schizophrenia
P3
Completed173Open-labelKarXT
NCT00061815
Study of Cetuximab, Oxaliplatin, 5-FU/LV Versus Oxaliplatin, 5-FU/LV in Patients With Previously Treated Metastatic, EGFR-Positive Colorectal Cancer
Colorectal Cancer
P3
Completed102RCT, Open-labelcetuximab, oxaliplatin, leucovorin, 5-fluorouracil, 5-fluorouracil, cetuximab
NCT06313996
A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma
Relapsed or Refractory Follicular Lymphoma
P3
Withdrawn—RCT, Single-blindCyclophosphamide, Doxorubicin, Vincristine, Rituximab, Prednisone, Bendamustine, Lenalidomide, Fludarabine, Liso-cel
NCT04659161
A Study to Assess Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adult Patients With Schizophrenia (EMERGENT-2)
Schizophrenia, Schizophrenia; Psychosis
P3
Completed252RCT, Double-blindXanomeline and Trospium Chloride Capsules, Placebo
NCT00063388
Phase II Study in Patients With Recurrent Non-Small-Cell Lung Cancer
Non-Small-Cell Lung Cancer
P2
Completed66Open-labelCetuximab
NCT00527111
Pre-op Rectal ChemoRad +/- Cetuximab
Rectal Cancer
P2
Completed139RCT, Open-labelCetuximab, 5-fluorouracil
NCT03370276
Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma
Squamous Cell Carcinoma of the Oropharynx, Squamous Cell Carcinoma of the Larynx
P1P2
Completed95Open-labelNivolumab, Cetuximab
NCT00797472
Study Comparing R-mabHD and a Combination of ABVD in Hodgkin's Disease
Hodgkin's Disease
P2
Unknown120RCT, Open-labelR-mabHD, ABVD
NCT00448097
Efficacy and Safety Study of Cetuximab or Cetuximab Plus Docetaxel to Treat Prostate Cancer Before Prostatectomy
Prostatic Neoplasms
P2
Terminated7RCT, Open-labelcetuximab, docetaxel
NCT00216203
Pemetrexed Plus Cetuximab in Patients With Recurrent Non Small Cell Lung Cancer
Non-Small Cell Lung Cancer
P1P2
Completed36Open-labelPemetrexed, Cetuximab
NCT00645593
Study of Gemcitabine and Cisplatin With or Without Cetuximab in Urothelial Cancer
Bladder Cancer
P2
Completed89RCT, Open-labelGemcitabine,, Cisplatin, Cetuximab
NCT00444678
Cetuximab Plus Biweekly Capecitabine and Oxaliplatin in KRAS Wild Type Metastatic Colorectal Cancer
Colorectal Cancer, Neoplasm Metastasis
P2
Completed36Open-labelCetuximab, Oxaliplatin, Capecitabine
NCT00193310
Preoperative or Postoperative Therapy of Patients With Stages IB, II, IIIA Non-Small Cell Lung Cancer
Lung Cancer
P2
Completed250RCT, Open-labelPaclitaxel, Carboplatin
NCT04151563
A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy
Carcinoma, Non-small Cell Lung Cancer
P1P2
Withdrawn—RCT, Open-labelnivolumab, ipilimumab, cabozantinib, docetaxel, ramucirumab, lucitanib
NCT00725400
Comparative Study of Cetuximab and Radiation Vs Surgery Before or After Radiation in Patients With Colorectal Carcinoma
Colorectal Carcinoma
P2
Withdrawn450RCT, Open-label—
NCT00857246
Pre-operation Chemo and Antibody Therapy Followed by Surgical Resection and Adjuvant Chemoradiation for Gastric Cancer
Gastric Cancer, Stomach Cancer
P2
Completed30Open-labelCetuximab, Irinotecan, Cisplatin, 5-FU
NCT00097227
Trial of Carboplatin/Paclitaxel/Cetuximab in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)
Non-small Cell Lung Cancer
P2
Completed165RCT, Open-labelCetuximab, Carboplatin, Paclitaxel
NCT00128856
Gemcitabine, Doxorubicin and Paclitaxel (GAT) as Neoadjuvant Treatment of Breast Cancer Patients
Breast Cancer
P2
Completed46Open-labelGemcitabine, Adriamycine, Paclitaxel
NCT00055419
A Study of Cetuximab in Patients Who Have Stage IV Colorectal Cancer
Colorectal Neoplasms
P2
Completed744Open-labelCetuximab
NCT03502746
Phase II Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma
Mesothelioma, Malignant
P2
Terminated34Open-labelNivolumab, Ramucirumab
NCT03697252
A Study to Assess Safety and Efficacy of KarXT in Adult Patients With Schizophrenia
Schizophrenia
P2
Completed182RCT, Double-blindXanomeline and Trospium Chloride Capsules, Placebo Capsules
NCT07603557
Study of Zola-cel (BMS-986353), in Participants With Autoimmune Cytopenia (Breakfree-AiCE)
Chronic Immune Thrombocytopenia, Autoimmune Hemolytic Anemia
P2
Not Yet Recruiting52Open-labelBMS-986353, Fludarabine Phosphate, Cyclophosphamide
NCT00148109
Trial of Cetuximab in Patients With Metastatic and/or Locally Advanced Soft Tissue and Bony Sarcomas
Sarcoma
P2
Completed36Open-labelCetuximab, Cetuximab
NCT00082212
A Study in Patients With Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma
Ovarian Cancer
P2
Terminated25Open-labelCetuximab
NCT00063401
Phase II Study in Patients With Epidermal Growth Factor Receptor (EGFR) + Advanced Stage Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Ovarian Cancer, Peritoneal Neoplasms
P2
Completed39Open-labelCetuximab:, Paclitaxel, Carboplatin
NCT00117962
Pemetrexed Disodium, Carboplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Stage III Non-Small Cell Lung Cancer
Lung Cancer
P2
Completed109RCT, Open-labelcetuximab, carboplatin, pemetrexed disodium
NCT00292955
Cetuximab, Cisplatin, and Radiotherapy in Women With Locally Advanced Cervical Carcinoma
Cancer of the Cervix
P2
Unknown30Open-labelCetuximab
NCT00083720
Erbitux (Cetuximab) Given Alone to Patients With EGFR-Negative Metastatic Colon or Rectal Cancer That is Refractory to Chemotherapy
Colorectal Neoplasms, Metastases
P2
Completed87Open-labelcetuximab
NCT00562419
CT-322 in Treating Patients With Recurrent Glioblastoma Multiforme and Combination Therapy With Irinotecan
Brain and Central Nervous System Tumors, Recurrent Glioblastoma Multiforme
P2
Unknown72RCT, Open-labelCT-322, irinotecan hydrochloride
NCT00097214
Carboplatin Plus Cetuximab for Treatment of Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)
Non-small Cell Lung Cancer
P2
Completed57Open-labelCarboplatin, Cetuximab
NCT00580073
Phase II Trial of Neoadjuvant FOLFOX4 and Cetuximab for Localized Adenocarcinoma of Rectum
Rectal Cancer
P2
Terminated6Open-labelFOLFOX4, Cetuximab
NCT02423343
A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular Carcinoma
Solid Tumor, Non-Small Cell Lung Cancer Recurrent
P1P2
Completed41Open-labelGalunisertib, Nivolumab
NCT05706753
A Study of Milvexian in Healthy Adult Females
Healthy Female
P1
Completed20Open-labelMilvexian, Midazolam, Ethinylestradiol, Drospirenone
NCT05375084
SHP2 Inhibitor BBP-398 in Combination With Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer With a KRAS Mutation
Non Small Cell Lung Cancer, Solid Tumor
P1
Terminated21Open-labelBBP-398 with nivolumab
NCT03338972
Immunotherapy With BCMA CAR-T Cells in Treating Patients With BCMA Positive Relapsed or Refractory Multiple Myeloma
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
P1
Completed28Open-labelAutologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143, Cyclophosphamide, Fludarabine
NCT03502577
BCMA-Specific CAR T-Cells Combined With a Gamma Secretase Inhibitor (JSMD194) to Treat Relapsed or Persistent Multiple Myeloma
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
P1
Terminated19Open-labelBCMA-specific CAR-expressing T Lymphocytes, Cyclophosphamide, Fludarabine, Gamma-Secretase Inhibitor LY3039478
NCT02831231
Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium
Schizophrenia
P1
Completed70RCT, Double-blindxanomeline tartrate, Trospium chloride
NCT06729970
A Study to Evaluate the Effects of Lithium, Valproic Acid, and Lamotrigine on the Pharmacokinetics of KarXT and Effects of KarXT on the Pharmacokinetics of Lithium, Valproic Acid, and Lamotrigine in Healthy Participants
Healthy Volunteers
P1
Completed133Open-labelXanomeline/Trospium Chloride, Lithium, Valproic Acid, Lamotrigine
NCT06605950
A Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of Xanomeline With Trospium Chloride Versus KarXT in Healthy Adult and Elderly Participants of Japanese Ethnicity and to Assess the Effect of Omeprazole on the PK of Xanomeline With Trospium Chloride in Healthy Adult Participants
Healthy Volunteers
P1
Completed78RCT, Double-blindKarXT, KarX-EC, Placebo, Omeprazole
NCT02706405
JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent Diffuse Large B-Cell Lymphoma
P1
Terminated30Open-labelAutologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014, Cyclophosphamide, Durvalumab, Fludarabine
NCT00374179
CT-322 in Treating Patients With Advanced Solid Tumors and Non-Hodgkin's Lymphoma
Cancer
P1
Completed40Open-labelCT-322
NCT00768911
CT-322 in Combination With Radiation Therapy and Temozolomide to Treat Newly Diagnosed Glioblastoma Multiforme
Glioblastoma Multiforme
P1
Unknown30Open-labelCT-322, Temozolomide
NCT07118215
A Study to Evaluate the Effects of KarXT on the Drug Levels of Midazolam, Fexofenadine, and Digoxin
Healthy Volunteers
P1
Completed62Open-labelKarXT, Midazolam, Fexofenadine, Digoxin
NCT03070327
BCMA Targeted CAR T Cells With or Without Lenalidomide for the Treatment of Multiple Myeloma
Multiple Myeloma
P1
Completed20Open-labelEGFRt/BCMA-41BBz CAR T cell, Cyclophosphamide, Lenalidomide.
NCT07848295
A Study to Assess the Safety and Tolerability of BMS-986527 in Participants With Clear Cell Renal Cell Carcinoma (ccRCC)
Clear Cell Renal Cell Carcinoma (ccRCC)
P1
Not Yet Recruiting112Open-labelBMS-986527, Nivolumab, Cabozantinib
NCT00291707
Trial of Cetuximab and Pemetrexed With Radiation in Head and Neck Cancer
Head and Neck Cancer
P1
Completed40Open-labelCetuximab, Pemetrexed
NCT03103971
huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia
Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent B-Cell Non-Hodgkin Lymphoma
P1
Terminated55Open-labelAutologous Human Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ T-lymphocytes, Cyclophosphamide, Fludarabine
NCT00211263
Bipolar Disorder Research Study for Ages 12 and Older
Bipolar Disorder
N/A
Completed750RCT, Open-labelmood stabilizer
NCT01565863
Progressive Goal Attainment Program for Veterans
Mental Disorders, Worries; Pain or Disability
N/A
Completed199RCT, Open-label—
NCT01281228
The Effect of GLP-1 Receptor Activation on Central Reward and Satiety in Obesity and Diabetes
Diabetes Mellitus, Diabetes Mellitus, Type 2
N/A
Completed48RCT, Single-blindexenatide, exenatide + exendin (9-39), placebo
NCT00149591
The Viability-Guided Angioplasty After Acute Myocardial Infarction-Trial (The VIAMI-Trial)
Myocardial Infarction, Coronary Artery Disease
N/A
Unknown300RCT, Open-label—
NCT05826756
Project PEER: Understanding the Lung Cancer Patient ExperiEnce in the Real-World Setting
Lung Cancer Patients, Caregivers
Unknown1,300——
NCT02075697
Spanish Registry of Systemic Treatments in Psoriasis
Psoriasis
Unknown3,500——
NCT04734769
Embryos With Preimplantation Genetic Testing for Aneuploidies (PGT-A) Inconclusive Result: Clinical Implications
Embryo Disorder
Unknown600——